Article
Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD
2024-03-26
Abstract excerpt
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a specific subgroup of patients with Autism Spectrum Disorder (ASD), namely ASD Phenotype 1 (ASD-Phen1). We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 1b study with two 14-day treatment phases (registered at clinicaltrials.gov as NCT04644003)...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a632b8e7-ee12-5167-a752-825ada7f7a4b
- DOI
- 10.20944/preprints202403.1581.v1
